Sign up to save your podcasts
Or
Share DESTINY-Breast11 and Surrogate Endpoints
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
DESTINY-Breast11 and Surrogate Endpoints
Thoughts on using pCR as a surrogate endpoint
DESTINY-Breast11: https://pubmed.ncbi.nlm.nih.gov/41130363/
Clinical Cancer Research publication on pCR, EFS and OS: https://aacrjournals.org/clincancerres/article/26/12/2838/82378/Pathologic-Complete-Response-after-Neoadjuvant
BMJ publication on pCR, EFS and OS: https://www.bmj.com/content/375/bmj-2021-066381
FDA-sponsored analysis: https://pubmed.ncbi.nlm.nih.gov/24529560/
KATHERINE trial: https://www.nejm.org/doi/full/10.1056/NEJMoa1814017
View all episodes
By Ming-Hei TaiThoughts on using pCR as a surrogate endpoint
DESTINY-Breast11: https://pubmed.ncbi.nlm.nih.gov/41130363/
Clinical Cancer Research publication on pCR, EFS and OS: https://aacrjournals.org/clincancerres/article/26/12/2838/82378/Pathologic-Complete-Response-after-Neoadjuvant
BMJ publication on pCR, EFS and OS: https://www.bmj.com/content/375/bmj-2021-066381
FDA-sponsored analysis: https://pubmed.ncbi.nlm.nih.gov/24529560/
KATHERINE trial: https://www.nejm.org/doi/full/10.1056/NEJMoa1814017